Biomarker-directed therapy: testing times

    loading  Checking for direct PDF access through Ovid

Abstract

The development and use of targeted drug therapies is on the increase, and in some cases is now the standard of care. The economic impact of this personalised medicine has attracted much interest over the past few years; however, policy issues related to the use of the diagnostic tests used to guide these targeted therapies are still evolving. At the 19th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [Montreal, Canada; May 2014] several presentations highlighted the role, use and economic impact of biomarkers tests used to inform personalised treatment decisions across a number of different settings.

Related Topics

    loading  Loading Related Articles